Epileptic Spasm clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 1-35
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
Los Angeles, California and other locations
Our lead scientists for Epileptic Spasm research studies include Rajsekar Rajaraman.